Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

Market Cap (In SEK)

1.92 Billion

Revenue (In SEK)

169.3 Million

Net Income (In SEK)

-53.6 Million

Avg. Volume

27.6 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
76.2-141.0
PE
-
EPS
-
Beta Value
0.738
ISIN
SE0016588867
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Fredrik Alpsten
Employee Count
-
Website
https://devyser.com
Ipo Date
2021-12-10
Details
Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.